Nasdaq
$0.8551▼ 1.94%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $9.9MShares out 11.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
19- 10.13Pre-market26.10.13 21:418-KKey event#●●●#●●●#●●●
Phio Pharmaceuticals Corp.Bullish
Phio Pharmaceuticals has successfully completed the production of its first commercial-scale cGMP batch of the drug substance PH-762. This milestone confirms the company's supply chain readiness and supports the planned initiation of its Phase 2b clinical trial in the first quarter of 2027.…more
$0.8551-1.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30After-hours26.10.01 05:014Ownership
Phio Pharmaceuticals Corp.
Insider Ronald Todd Plott of Phio Pharmaceuticals Corp. reported a change in beneficial ownership of securities effective September 28, 2026. This filing formalizes the disclosure of insider equity transactions via Form 4.…more
$0.8551-1.94%vs prev closeView filingShare - 9.29After-hours26.09.30 05:014Ownership
Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. executive Lisa Cabott Carson reported a change in beneficial ownership of securities as of September 28, 2026. This filing serves as a Form 4 statement regarding the insider's stock holdings.…more
$0.8551-1.94%vs prev closeView filingShare
18 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.14Pre-market26.09.14 20:07#●●●#●●●
Phio Advances PH-762 Clinical Development with FDA Submission
Phio has submitted documentation to the FDA to support the next stage of clinical development for its PH-762 treatment in cutaneous squamous cell carcinoma. As this represents a procedural milestone without finalized clinical results, the outlook remains neutral.…more
$0.8551-1.94%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga